Therein, glioblastoma with a constitutively activated ERK, e.g., the glioblastoma characterized by EGFR/PDGFR amplification or oncogenic mutations, may result as both resistant to targeted-therapy and immune-resistant. The gene discussed is EGFR; the disease is glioblastoma.